Stock Events

Stock Events

Vir Biotechnology 

$9.21
126
+$0.19+2.11% Today

Statistics

Day High
9.21
Day Low
8.65
52W High
10.94
52W Low
4.16
Volume
415,117
Avg. Volume
3,581,881
Mkt Cap
1.28B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Dividends

0%Dividend Yield
Dec 10
$0.03
Sep 10
$0.03
Jun 10
$0.03
Mar 10
$0.03
Dec 9
$0.03
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

30AprExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-1.56
-1.07
-0.58
-0.1
Expected EPS
-0.0955
Actual EPS
N/A

Financials

-638.87%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
137.11MRevenue
-875.97MNet Income

Analyst Ratings

$22.00Average Price Target
The highest estimate is 30.00.
From 5 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow VIR. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences is a direct competitor in the antiviral drug market, focusing on treatments for HIV, hepatitis B, hepatitis C, and influenza, similar to Vir's focus on infectious diseases.
Moderna
MRNA
Mkt Cap10.61B
Moderna is known for its mRNA technology used in vaccines, directly competing with Vir's efforts in developing treatments and vaccines for infectious diseases.
BioNTech
BNTX
Mkt Cap24.99B
BioNTech competes in the infectious disease space with its mRNA technology for vaccines, similar to Vir's focus areas.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals competes with Vir in developing monoclonal antibodies for the treatment of infectious diseases, including COVID-19.
Novavax
NVAX
Mkt Cap1.36B
Novavax is a competitor in the vaccine space, particularly for COVID-19, directly competing with Vir's efforts in infectious disease vaccines.
Pfizer
PFE
Mkt Cap140.15B
Pfizer competes across a broad range of therapeutic areas including vaccines for infectious diseases, making it a competitor to Vir.
Johnson & Johnson
JNJ
Mkt Cap455.04B
Johnson & Johnson, through its pharmaceutical division Janssen, competes in the development of vaccines and treatments for infectious diseases.
Astrazeneca
AZN
Mkt Cap256.58B
AstraZeneca is involved in the development of vaccines and treatments for various infectious diseases, competing with Vir's focus areas.
Sanofi
SNY
Mkt Cap124.45B
Sanofi competes with Vir in the infectious disease sector, particularly in the development of vaccines and treatments for various diseases.
Abbott Laboratories
ABT
Mkt Cap214.96B
Abbott Laboratories competes with Vir in the broader healthcare sector, including diagnostics and treatments for infectious diseases.

About

Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.
Show more...
CEO
Dr. Marianne De Backer M.B.A., M.Sc., Ph.D.
Employees
408
Country
US
ISIN
US92764N1028

Listings

XNAS
US
VIR
MX
MX
VIR.MX
BOATS
BOATS
VIR.BOATS

0 Comments

Share your thoughts

FAQ

What is Vir Biotechnology stock price today?▼
The current price of VIR is $9.21 USD — it has increased by +2.11% in the past 24 hours. Watch Vir Biotechnology stock price performance more closely on the chart.
What is Vir Biotechnology stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Vir Biotechnology stocks are traded under the ticker VIR.
Is Vir Biotechnology stock price growing?▼
VIR stock has risen by +2.34% compared to the previous week, the month change is a -1.82% fall, over the last year Vir Biotechnology has showed a +41.51% increase.
What is Vir Biotechnology market cap?▼
Today Vir Biotechnology has the market capitalization of 1.28B
When is the next Vir Biotechnology earnings date?▼
Vir Biotechnology is going to release the next earnings report on April 30, 2026.
What were Vir Biotechnology earnings last quarter?▼
VIR earnings for the last quarter are -0.31 USD per share, whereas the estimation was -0.49 USD resulting in a +36.88% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Vir Biotechnology revenue for the last year?▼
Vir Biotechnology revenue for the last year amounts to 137.11M USD.
What is Vir Biotechnology net income for the last year?▼
VIR net income for the last year is -875.97M USD.
Does Vir Biotechnology pay dividends?▼
Yes, VIR dividends are paid quarterly. The last dividend per share was 0.03 USD. As of today, Dividend Yield (FWD)% is 0%.
How many employees does Vir Biotechnology have?▼
As of April 02, 2026, the company has 408 employees.
In which sector is Vir Biotechnology located?▼
Vir Biotechnology operates in the Health Care sector.
When did Vir Biotechnology complete a stock split?▼
Vir Biotechnology has not had any recent stock splits.
Where is Vir Biotechnology headquartered?▼
Vir Biotechnology is headquartered in San Francisco, US.